Extraordinary general meeting in Cantargia AB (publ)
The extraordinary general meeting in Cantargia on 13 October 2020 resolved in accordance with the following:
- to elect Flavia Borellini as new board member of the company.
- that remuneration to Flavia Borellini shall be paid with USD 25,000 (or the equivalent amount in SEK) per year. In addition, a remuneration of USD 20,000 (or the equivalent amount in SEK) per year shall be paid to Flavia Borellini for her chairmanship and work in a Drug Development Committee, to be established by the company.
- to issue not more than 1,900,000 warrants and approve that the company, directly or indirectly, transfers warrants and/or shares to the participants in the employee option program which was resolved on by the 2020 annual general meeting (Employee Option Program 2020/2023).
For more information on the new board member and the warrants, refer to the notice to the meeting.
For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. The main project, the antibody CAN04, is being studied in the clinical phase I/IIa CANFOUR study with a primary focus on non-small cell lung cancer and pancreatic cancer. The study is focused on combination therapies, but also includes a monotherapy arm. Positive interim data from the combination therapies were presented in December 2019. Cantargia’s second project, the antibody CAN10, addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at http://www.cantargia.com.